Who are Nandrolon Phenylpropionate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prasterone (DHEA), Micronized, Dehydroepiandrosterone (DHEA), DHEA (1.0%), DHEA treatment, Dehydroepiandrosterone (DHEAS), Talazoparib with enzalutamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nandrolone-phenpropionate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nandrolon Phenylpropionate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nandrolon Phenylpropionate (NANDROLONE PHENPROPIONATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen. Area: Bone.

marketed Androgen Androgen receptor, Estrogen receptor Bone Small molecule Live · refreshed every 30 min

Target snapshot

Nandrolon Phenylpropionate (NANDROLONE PHENPROPIONATE) — Merck & Co.. Nandrolone Phenylpropionate works by binding to androgen receptors in the body, mimicking the effects of male hormones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nandrolon Phenylpropionate TARGET	NANDROLONE PHENPROPIONATE	Merck & Co.	marketed	Androgen	Androgen receptor, Estrogen receptor	1959-01-01
Prasterone (DHEA), Micronized	Prasterone (DHEA), Micronized	Hospital Clinic of Barcelona	marketed	Steroid hormone precursor	Androgen receptor, estrogen receptor (indirect via metabolic conversion)
Dehydroepiandrosterone (DHEA)	Dehydroepiandrosterone (DHEA)	Boston Children's Hospital	marketed	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (indirect via peripheral conversion)
DHEA (1.0%)	DHEA (1.0%)	EndoCeutics Inc.	phase 3	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (via peripheral conversion)
DHEA treatment	DHEA treatment	University Hospital, Bordeaux	phase 3	Steroid hormone / Hormone replacement	Androgen receptor, Estrogen receptor (indirect via metabolite conversion)
Dehydroepiandrosterone (DHEAS)	Dehydroepiandrosterone (DHEAS)	Taipei Veterans General Hospital, Taiwan	phase 3	Endogenous steroid hormone / Adrenal hormone replacement	Androgen receptor, Estrogen receptor (indirect via peripheral conversion)
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen class)

· 4 drugs in this class
Azurity · 1 drug in this class
Endo · 1 drug in this class
Marius · 1 drug in this class
Merck & Co. · 1 drug in this class
The Affiliated Hospital of Qingdao University · 1 drug in this class
Woodward Specl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nandrolon Phenylpropionate — Competitive Intelligence Brief. https://druglandscape.com/ci/nandrolone-phenpropionate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab